stockportfolio.pro
Stocks / ACRS vs BBOT
ACRS vs BBOT
Aclaris Therapeutics, Inc. and BridgeBio Oncology Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Aclaris Therapeutics, Inc. (ACRS) | BridgeBio Oncology Therapeutics, Inc. (BBOT) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $7.83M | $0 |
| Net income (latest FY) | $-64.92M | $-134.04M |
| Revenue growth (5y CAGR) | 3.8% | — |
| Net margin | -829.6% | — |
| Return on equity | -63.0% | -32.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ACRS — free Open BBOT — freeFrequently asked questions
Which is bigger, ACRS or BBOT?
BridgeBio Oncology Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, ACRS or BBOT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.